~~<i id='8A97103E14'><strike id='8A97103E14'><tt id='8A97103E14'><pre id='8A97103E14'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：hotspot 2025-10-02 01:22:29 Page View：69557

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 2023 STAT Wunderkinds: get to know the winners
Next article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Wikipedia

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

FDA warns J&J's Abiomed: We will regulate your software

Abiomed,whichwasboughtbyJohnson&Johnsonlatelastyearfor$16.6billion,sellsdevicesforheartfailurepa

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Medicare drug price negotiation hearing pits pharma v Biden admin

AdobeTRENTON,N.J.—PharmaindustrygiantsincludingBristolMyersSquibb,Johnson&Johnson,Novartis,andNo

WSS

leisure time

leisure time

focus

Wikipedia

Medicare drug price negotiation hearing pits pharma v Biden admin